Barbara Cvenkel

Glaucoma is the second leading cause of blindness in people over 50 years of age worldwide, and with the ageing population, this number will continue to rise, resulting in a reduced quality of life for these people and an increased social and economic burden on society [1,2]. Since visual impairment due to glaucoma is preventable, timely detection and treatment is critical.

4. Discussion The population is ageing and the prevalence of age-related diseases, including glaucoma, is increasing. Since life expectancy is extending, timely detection and treatment of glaucoma is of increasing importance. DRSPs provide an opportunity to detect undiagnosed glaucoma cases. Our study found that 209 out of a total of 2074 patients (10.1%) had optic disc features suspicious for glaucoma on retinal images, which is consistent with the reports of some other studies. Park et al.

7. Discussion Similarly to other chronic diseases, nonadherence to medication is a challenge to effective treatment of glaucoma. There are many barriers to adherence that need to be detected and the approach individually tailored [19]. The purpose of this review is to highlight different approaches to address adherence and relieve the burden of long-term frequent drop administration (Table 1). However, many of these approaches are still undergoing clinical trials.